Abstract |
Although chemotherapy has been generally of limited clinical benefit in the treatment of metastatic malignant melanoma (MMM), fotemustine (FM) is a newly developed drug which is active against this disease. Twenty-four patients with histologically proven MMM were treated with fotemustine, with or without dacarbazine ( DITC) according to different phase II trials. In the first schedule, three patients received FM alone on days 1, 8, 15 followed by a 5-week rest period. The second schedule consisted of FM administered on days 1 and 8 alternating with DTIC on days 15 and 16, followed by a 5-week rest period (19 patients). The third schedule, given to two patients, consisted of DTIC followed 4 h later by FM. The overall response rate was 8.3%. Response in those who were treated with alternating drugs, included one partial response (PR) in the brain which lasted 4 months, and one PR in brain metastases with complete response (CR) in lymph nodes for 4 months. Clinical and radiological evidence of regression was observed mainly in brain metastases (22.2%), reflecting the intracerebral activity of the drug. It seems that fotemustine is superior to any other drug currently available in the treatment of these metastases.
|
Authors | O Merimsky, M Inbar, B Gerard, S Chaitchik |
Journal | Melanoma research
(Melanoma Res)
Vol. 2
Issue 5-6
Pg. 401-6
(Dec 1992)
ISSN: 0960-8931 [Print] England |
PMID | 1292787
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Nitrosourea Compounds
- Organophosphorus Compounds
- Dacarbazine
- fotemustine
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Brain Neoplasms
(drug therapy, radiotherapy, secondary)
- Dacarbazine
(administration & dosage)
- Female
- Humans
- Male
- Melanoma
(drug therapy, pathology, radiotherapy)
- Middle Aged
- Nitrosourea Compounds
(administration & dosage, therapeutic use)
- Organophosphorus Compounds
(administration & dosage, therapeutic use)
- Skin Neoplasms
(drug therapy, pathology, radiotherapy)
|